Fig. 8. PLX3397 results in ablation of CX3CR1^GFP-positive cells and significant reduction in cisplatin accumulation in the kidney (experiment 2).

(A) Representative images of renal CX3CR1^GFP-positive cells (arrowheads), identified through immunohistochemical staining. Scale bars, 50 μm. (B) The number of CX3CR1^GFP-positive cells in each field was quantified. Data are expressed as means ± SD, n = 4 to 5 kidney samples (2 females and 2 to 3 males) per experimental group (total 17 mice; 8 females and 9 males). Compared to control mice (saline/vehicle-treated mice), PLX3397 treatment in saline-treated mice and cisplatin-treated mice ablated 95.63 and 82.52% of CX3CR1^GFP-positive cells, respectively. HPF, high-power field (the area of a slide visible under ×400 magnification of corticomedullary junction). (C) Platinum levels in the kidney tissues were analyzed by ICP-MS. Data are expressed as means ± SD, n = 5 to 6 blood and kidney samples (2 to 3 females and 2 to 3 males) per experimental group (total 22 mice; 11 females and 11 males). Cisplatin resulted in increased platinum in the kidney, while PLX3397 significantly reduced cisplatin accumulation. Platinum levels were normalized to sulfur contained in the kidney. Data are expressed as means ± SE. P values were calculated using one-way ANOVA with Tukey’s multiple comparisons test.